(Reuters) – Sanofi announced on Tuesday, before the opening of an investor day dedicated to its immunology portfolio, a revision of its business objective for its now expected asthma and atopic dermatitis treatment Dupixent “more of 13 billion euros at a growing rate”.
“This new ambition does not take into account the potential for increased sales related to chronic obstructive pulmonary disease (COPD), whose results from pivotal clinical trials are expected in 2023”, underlines the laboratory in its press release.
Sanofi, which was largely left behind in the race for mRNA vaccines against the coronavirus responsible for COVID-19 at the start of the pandemic, also announced, in a separate press release, that it had signed a collaboration agreement with the American biotech company IGM Biosciences to develop new therapeutic agents based on IgM (immunoglobulins M) in oncology, immunology and inflammation.
(Report Sudip Kar Gupta, written by Myriam Rivet, told by Nicolas Delame)